Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
08/06/2020 08/07/2020 08/10/2020 08/11/2020 08/12/2020 Date
86.4(c) 87.38(c) 86.72(c) 87.63(c) 87.41 Last
1 816 878 2 019 201 1 027 552 1 570 817 390 006 Volume
-1.23% +1.13% -0.76% +1.05% -0.25% Change
More quotes
Financials
Sales 2020 36 907 M 43 368 M 43 368 M
Net income 2020 10 949 M 12 865 M 12 865 M
Net Debt 2020 4 237 M 4 978 M 4 978 M
P/E ratio 2020 10,3x
Yield 2020 3,65%
Sales 2021 38 737 M 45 518 M 45 518 M
Net income 2021 5 914 M 6 949 M 6 949 M
Net Debt 2021 2 600 M 3 055 M 3 055 M
P/E ratio 2021 18,0x
Yield 2021 3,84%
Capitalization 110 B 130 B 129 B
EV / Sales 2020 3,10x
EV / Sales 2021 2,91x
Nbr of Employees 100 409
Free-Float 88,9%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs; - human vaccines (15.9%): pediatric vaccines,... 
Sector
Pharmaceuticals
Calendar
10/29Earnings Release
More about the company
Surperformance© ratings of Sanofi
Trading Rating : Investor Rating :
More Ratings
Latest news on SANOFI
04:08aSANOFI : Solicitor Representing Sodium Valproate Patient Groups Comments On Sano..
AQ
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
RE
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
RE
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
RE
08/05U.S. to pay $1 billion for 100 million doses of J&J's COVID-19 vaccine candid..
RE
08/05Regeneron 2Q Profit Surges on Collaborations
DJ
08/05Regeneron profit beats, expects early results from COVID-19 trials in Septemb..
RE
08/05COVID-19 VACCINE TRIALS HAVE A PROBL : Minority Groups Don't Trust Them
DJ
08/03SANOFI : Credit Suisse reaffirms its Buy rating
MD
08/03SANOFI : formally investigated over epilepsy drug Depakine
RE
08/03SANOFI : formally investigated over epilepsy drug Depakine
RE
08/03Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
DJ
08/03SANOFI : and GSK in advanced discussions with European Union to supply up to 30..
AQ
08/03GlaxoSmithKline and Sanofi to Supply EU With 300 Million Covid-19 Doses
DJ
08/01WHAT'S NEWS : World-Wide -- WSJ
DJ
More news
News in other languages on SANOFI
04:08aSANOFI : Solicitor Representing Sodium Valproate Patient Groups Comments On Sano..
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
08/11MODERNA : Coronavirus-Les USA ont commandé des doses du potentiel vaccin de Mode..
08/11MODERNA : Les USA ont commandé des doses du potentiel vaccin de Moderna, dit Tru..
08/10Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in Sept..
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 07/27
Back towards the lower end of the range
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 104,86 €
Last Close Price 87,63 €
Spread / Highest target 40,2%
Spread / Average Target 19,7%
Spread / Lowest Target -3,00%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-2.22%129 583
JOHNSON & JOHNSON1.48%386 946
ROCHE HOLDING AG-0.35%292 091
PFIZER, INC.-3.55%209 994
MERCK & CO., INC.-11.04%204 641
NOVARTIS AG-17.07%183 277